Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.46, delivering a surprise of -21.05%.Over the last four quarters, the company ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION Indicate by check mark whether the registrant (1) has filed all reports required to ...

Exhibit 99.1 Corporate Updates Awaiting FDA action on NDA for YUTREPIA (treprostinil) inhalation powder On March 28, 2025, the U.S. Food and Drug Administration (FDA) accepted Liquidia's New Drug Application (NDA) resubmission for YUTREPIA (treprostinil) inhalation powder to treat PAH and PH-ILD as a complete Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 202 ...

Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceut ...

Core Insights - The article discusses potential investment opportunities in LQDA, indicating a possible long position may be initiated within the next 72 hours [1]. Group 1 - The analyst has no current stock, option, or similar derivative position in any of the companies mentioned [1]. - The article expresses the author's own opinions and is not receiving compensation from any company mentioned [1]. - There is an indication of a potential beneficial long position through stock or call options in LQDA [1].

Liquidia Technologies, Inc. (LQDA) shares rallied 13.2% in the last trading session to close at $15.83. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.1% loss over the past four weeks.Last week, the company announced that the U.S. District Court for the District of Columbia dismissed the cross-claim filed by United Therapeutics that seeks to challenge Liquidia’s amendment to its new drug application for Yu ...

Core Viewpoint - Liquidia Corporation has received a favorable ruling from the U.S. District Court, which dismissed United Therapeutics' cross-claim against its New Drug Application (NDA) for YUTREPIA, allowing the company to proceed with its plans for the drug's approval [1][2]. Group 1: Legal Developments - The U.S. District Court dismissed United Therapeutics' cross-claim regarding Liquidia's amendment to its NDA for YUTREPIA, determining that the claim was unripe and lacked standing [1][2]. - United Therapeutics retains the right to appeal the court's decision [2]. Group 2: Product Development and Approval Timeline - The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the YUTREPIA NDA on May 24, 2025, following the expiration of regulatory exclusivity on May 23, 2025 [3][6]. - Liquidia aims for YUTREPIA to become the preferred treatment for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2][4]. Group 3: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a particular emphasis on pulmonary hypertension [4]. - The company is also working on L606, a sustained-release formulation of treprostinil, and markets a generic version of Treprostinil Injection for PAH treatment [4].

Core Points - Liquidia Corporation will report its first quarter 2025 financial results on May 8, 2025, and will host a webcast at 8:30 a.m. Eastern Time to discuss these results and provide a corporate update [1][2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's primary focus includes the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company is currently developing and commercializing products for pulmonary hypertension and other applications using its proprietary PRINT Technology [3] Product Development - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, which is an investigational drug aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also working on L606, an investigational sustained-release formulation of treprostinil that is administered twice daily with a next-generation nebulizer [3] - Additionally, Liquidia markets a generic version of Treprostinil Injection for the treatment of PAH [3] Upcoming Events - Liquidia will present an overview of its business at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, at 8:45 a.m. ET [1] - Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website, with an archived version accessible for at least 30 days post-event [2]

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company is currently developing and commercializing products for pulmonary hypertension and other applications using its proprietary PRINT Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also working on L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3] Upcoming Events - Liquidia will present an overview of its business at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, at 8:45 a.m. ET [1] - Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website, with an archived version accessible for at least 30 days post-event [2]